NCT03133988: Margetuximab Expanded Access Program

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Approved for marketing

Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: null
Age: Child, Adult), Senior)
Location of Metastases: 
Additional Notes: Patient must have received at least 2 prior lines of anti-HER2 directed therapy in the metastatic setting; Patient must have prior treatment with at least one, & no more than three, lines of therapy overall in the metastatic setting
Exclusions: Patients with known untreated brain metastasis

Comments are closed.

Up ↑